Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
SUNNYVALE, CA—Chao Xingjuan, President and CEO of Ceribell, Inc. (NASDAQ:CBLL), executed a significant stock sale on June 3, 2025, according to a recent SEC filing. Xingjuan sold 25,000 shares of common stock at a weighted average price of $17.00 per share, amounting to a total transaction value of $425,000. The shares were sold in multiple transactions at prices ranging from $16.81 to $17.20. According to InvestingPro data, the company maintains impressive gross profit margins of 87% and strong liquidity, with current assets significantly exceeding short-term obligations. The stock currently appears overvalued based on InvestingPro’s Fair Value analysis.
In addition to the stock sale, Xingjuan exercised stock options to acquire 25,000 shares at a price of $2.24 per share, which were subsequently sold as part of the same transaction. Following these transactions, Xingjuan holds a direct ownership of 776,022 shares of Ceribell’s common stock. The transactions were conducted under a prearranged 10b5-1 trading plan. Analyst consensus remains bullish on the stock, with price targets ranging from $26 to $36, though net income is expected to decline this year. Get deeper insights and access to comprehensive financial analysis with InvestingPro’s detailed research reports, available for over 1,400 US stocks.
In other recent news, Ceribell reported a significant 42% year-over-year increase in total revenue for the first quarter of 2025, amounting to $20.5 million. Despite a net loss of $12.8 million, the company raised its full-year revenue guidance to between $83 million and $87 million. Ceribell’s gross margin stood at an impressive 88%, and the firm received FDA clearance for a new pediatric seizure detection algorithm. TD Cowen reaffirmed its Buy rating for Ceribell, maintaining a $36 price target and expressing optimism about the potential easing of trade tensions between the US and China. Analysts from TD Cowen noted the company’s resilience in maintaining strong financial health, even amid tariff challenges. Ceribell’s management remains confident in sustaining growth, supported by its leadership in EEG technology and strategic investments. Investors are closely monitoring the ongoing US-China trade discussions, which could favorably impact Ceribell’s cost structure and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.